OS Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2022	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	11.25	3.97	1.13	1.15	1.5	795.42
Research & Development	8.43	2.84	3.22	3.29	2.17	601.78
Other Operating Expenses	-	-	-	0	1.16	4,250
Total Operating Expenses	19.68	6.81	4.34	4.45	4.84	5,647
Operating Income	-19.68	-6.81	-4.34	-4.45	-4.84	-5,647
Interest Income	0	-	0	-	-	61.29
Interest Expense	-0.01	-2.05	-3.45	-1.81	-2.58	-461.79
Other Non-Operating Income (Expense)	1.42	-0.02	-	-	-	20
Total Non-Operating Income (Expense)	1.42	-2.07	-3.45	-1.81	-2.58	-380.5
Pretax Income	-18.27	-8.88	-7.79	-6.25	-7.42	-6,028
Net Income	-20.26	-10.89	-7.92	-6.38	-7.51	-6,028
Net Income Attributable to Preferred Dividends	-	2	0.13	0.13	0.09	-
Net Income to Common	-20.26	-10.89	-7.92	-6.38	-7.51	-6,028
Shares Outstanding (Basic)	25	12	5	5	5	4
Shares Outstanding (Diluted)	25	12	5	5	5	4
Shares Change (YoY)	169.23%	127.98%	8.80%	-	27.82%	-
EPS (Basic)	-0.82	-0.88	-1.46	-1.28	-1.50	-1.42
EPS (Diluted)	-0.82	-0.88	-1.46	-1.28	-1.50	-1.42
Free Cash Flow	-12.88	-7.28	-3.01	-3.79	-4.41	-2.42
Free Cash Flow Per Share	-0.51	-0.59	-0.55	-0.76	-0.88	-0.62
EBITDA	-19.44	-6.81	-4.34	-4.45	-4.84	-5,647
EBIT	-19.68	-6.81	-4.34	-4.45	-4.84	-5,647

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q